摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

9-chloro-3,5-dihydro-1-methyl-7-phenylpyrimido[1,2-a]-[1,4]benzodiazepin-3-one | 41715-40-6

中文名称
——
中文别名
——
英文名称
9-chloro-3,5-dihydro-1-methyl-7-phenylpyrimido[1,2-a]-[1,4]benzodiazepin-3-one
英文别名
9-chloro-1-methyl-7-phenylpyrimido[1,2-a][1,4]benzodiazepin-3(5H)-one;9-chloro-1-methyl-7-phenyl-5H-benzo[f]pyrimido[1,2-a][1,4]diazepin-3-one;9-Chlor-3,5-dihydro-1-methyl-7-phenyl-pyrimido<1,2-a>-<1,4>benzodiazepin-3-on;9-chloro-1-methyl-7-phenyl-5H-pyrimido[1,2-a][1,4]benzodiazepin-3-one
9-chloro-3,5-dihydro-1-methyl-7-phenylpyrimido[1,2-a]-[1,4]benzodiazepin-3-one化学式
CAS
41715-40-6
化学式
C19H14ClN3O
mdl
——
分子量
335.793
InChiKey
AGKCEXFDBNQHOU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    24
  • 可旋转键数:
    1
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.11
  • 拓扑面积:
    45
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

反应信息

  • 作为反应物:
    描述:
    2-amino-7-nitro-5-(2,6-difluorophenyl)-3H-1,4-benzodiazepine 、 4-己炔酸9-chloro-3,5-dihydro-1-methyl-7-phenylpyrimido[1,2-a]-[1,4]benzodiazepin-3-oneN,N'-羰基二咪唑 作用下, 以 tetrahydrofuran-di-methylformamide 为溶剂, 生成 9-nitro-1-propyl-7-(2,6-difluorophenyl)pyrimido[1,2-a][1,4]benzodiazepin-3(5H)-one
    参考文献:
    名称:
    7-phenylpyrimido[1,2-alpha][1,4]benzodiazepin-3(5H)-ones
    摘要:
    化合物II的结构式为:##STR1## 其中R.sub.o选自羟基,1到3个碳原子的烷基,--COOR,其中R为上述定义的烷基,##STR2## 其中n为1到4的数字,R.sub.6和R.sub.7为氢或上述定义的烷基,或一起##STR3## 选自吡咯烷基,哌啶基,吗啉基和4-甲基哌嗪基,和--CH.sub.2 OH;其中R.sub.1选自羟基,乙酰氧基,丙酰氧基,琥珀酰氧基和其烷基酯类;其中R.sub.2,R.sub.3,R.sub.4和R.sub.5选自氢,卤素,硝基,氰基,三氟甲基,低烷基,-烷氧基,-烷基硫基,-烷基亚磺酰基,-烷基磺酰基,-烷酰氨基和-二烷基氨基,通过将公式I的2-氨基-5-苯基-3H-1,4-苯二氮平与选自公式HC.tbd.C--COOR,ROOC.tbd.C--COOR的乙炔化合物以及##STR5## 其中R'为上述定义的烷基或##STR6## 定义如上的化合物缩合而成,得到公式IIa的化合物##STR7## 其中R.sub.2,R.sub.3,R.sub.4和R.sub.5如上所定义,Ro'选自氢,如上定义的烷基,--COOR,以及##STR8## 如上定义的化合物。其中R.sub.o为--CH.sub.2 OH的化合物是通过还原R.sub.o'为--COOR的化合物IIa得到的。化合物II及其药学上可接受的酸盐和N-氧化物是对鸟类和哺乳动物有用的镇静剂和镇痛剂。
    公开号:
    US04978753A1
  • 作为产物:
    参考文献:
    名称:
    Benzodiazepine derivatives
    摘要:
    本发明涉及以下化合物的嘧啶并苯二氮平衍生物(I)和2-(N-乙酰乙酰)氨基苯二氮平衍生物(II),其化合物具有以下公式: 其中R1代表氢原子或较低的烷基,R2代表氢原子、较低的烷基或芳基,环A和/或B未取代或被一个或多个卤素、硝基、三氟甲基、较低烷基或较低烷氧基所取代;包括化合物(I)的6-位氮原子或化合物(II)的4-位氮原子可以形成N-氧化物的情况,以及化合物(I)可以以其药学上可接受的酸加盐形式存在。本发明还涉及一种制备这些化合物的方法。化合物(I)和(II)可用作肌肉松弛剂、抗惊厥药、镇静剂、安定剂等。
    公开号:
    US04175079A1
点击查看最新优质反应信息

文献信息

  • NATSUGARI H.; MEGURO K.; KUWADA Y., CHEM. AND PHARM. BULL., 1979, 27, NO 12, 2927-2937
    作者:NATSUGARI H.、 MEGURO K.、 KUWADA Y.
    DOI:——
    日期:——
  • US4175079A
    申请人:——
    公开号:US4175079A
    公开(公告)日:1979-11-20
  • US4978753A
    申请人:——
    公开号:US4978753A
    公开(公告)日:1990-12-18
  • 7-phenylpyrimido[1,2-alpha][1,4]benzodiazepin-3(5H)-ones
    申请人:The Upjohn Company
    公开号:US04978753A1
    公开(公告)日:1990-12-18
    A 7-phenylpyrimido[1,2-a][1,4]benzodiazepin-3(5H)-ones of the formula II: ##STR1## wherein R.sub.o is selected from the group consisting of hydrogen, alkyl of 1 to 3 carbon atoms, inclusive, --COOR in which R is alkyl defined as above, ##STR2## in which n is a number of 1 to 4, R.sub.6 and R.sub.7 are hydrogen or alkyl defined as above or together ##STR3## is selected from the group consisting of pyrrolidino, piperidino, morpholino, and 4-methylpiperazino, and --CH.sub.2 OH; wherein R.sub.1 is selected from the group consisting of hydrogen, hydroxy, acetoxy, propionoxy, succinyloxy, and alkyl esters thereof; wherein R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are selected from the group consisting of hydrogen, halogen, nitro, cyano, trifluoromethyl, lower-alkyl, -alkoxy, -alkylthio, -alkylsulfinyl, -alkylsulfonyl, -alkanoylamino and -dialkylamino, are synthesized by condensing a 2-amino-5-phenyl-3H-1,4-benzodiazepine of the formula I ##STR4## with a compound selected from the group consisting of acetylenic compounds of the formulae HC.tbd.C--COOR, ROOC.tbd.C--COOR in which R is alkyl defined above, inclusive, and ##STR5## in which R' is alkyl defined as above or ##STR6## defined as above, to give a compound of formula IIa ##STR7## wherein R.sub.2, R.sub.3, R.sub.4, and R.sub.5 is defined as above, and Ro' is selected from the group consisting of hydrogen, alkyl as defined above, --COOR as defined above, and ##STR8## as defined above. Compounds of formula II wherein R.sub.o is --CH.sub.2 OH are obtained by reducing a compound IIa wherein R.sub.o is --CH.sub.2 OH are obtained by reducing a compound IIa wherein R.sub.o ' is --COOR. The compounds of formula II and their pharmacologically acceptable acid addition salts and N-oxides are useful tranquilizers and sedatives for birds and mammals.
    化合物II的结构式为:##STR1## 其中R.sub.o选自羟基,1到3个碳原子的烷基,--COOR,其中R为上述定义的烷基,##STR2## 其中n为1到4的数字,R.sub.6和R.sub.7为氢或上述定义的烷基,或一起##STR3## 选自吡咯烷基,哌啶基,吗啉基和4-甲基哌嗪基,和--CH.sub.2 OH;其中R.sub.1选自羟基,乙酰氧基,丙酰氧基,琥珀酰氧基和其烷基酯类;其中R.sub.2,R.sub.3,R.sub.4和R.sub.5选自氢,卤素,硝基,氰基,三氟甲基,低烷基,-烷氧基,-烷基硫基,-烷基亚磺酰基,-烷基磺酰基,-烷酰氨基和-二烷基氨基,通过将公式I的2-氨基-5-苯基-3H-1,4-苯二氮平与选自公式HC.tbd.C--COOR,ROOC.tbd.C--COOR的乙炔化合物以及##STR5## 其中R'为上述定义的烷基或##STR6## 定义如上的化合物缩合而成,得到公式IIa的化合物##STR7## 其中R.sub.2,R.sub.3,R.sub.4和R.sub.5如上所定义,Ro'选自氢,如上定义的烷基,--COOR,以及##STR8## 如上定义的化合物。其中R.sub.o为--CH.sub.2 OH的化合物是通过还原R.sub.o'为--COOR的化合物IIa得到的。化合物II及其药学上可接受的酸盐和N-氧化物是对鸟类和哺乳动物有用的镇静剂和镇痛剂。
  • Benzodiazepine derivatives
    申请人:Takeda Chemical Industries, Ltd.
    公开号:US04175079A1
    公开(公告)日:1979-11-20
    The present invention relates to pyrimidobenzodiazepine derivatives of the formula (I) and 2-(N-acetoacetal)aminobenzodiazepine derivatives of the formula (II), which compounds have the following formulas: ##STR1## wherein R.sup.1 represents a hydrogen atom or a lower alkyl group, R.sup.2 represents a hydrogen atom, a lower alkyl group or an aryl group, and rings A and/or B are unsubstituted or substituted by one or more of a halogen, nitro, trifluoromethyl, lower alkyl or lower alkoxy group; including the cases wherein the nitrogen atom at the 6-position of the compound (I) or the 4-position of the compound (II) may be in the form of N-oxide and wherein compound (I) may be in the form of a pharmaceutically acceptable acid addition salt thereof. The present invention also relates to a method of producing these compounds. The compounds (I) and (II) are useful as muscle relaxants, anticonvulsants, sedatives, tranquilizers, etc.
    本发明涉及以下化合物的嘧啶并苯二氮平衍生物(I)和2-(N-乙酰乙酰)氨基苯二氮平衍生物(II),其化合物具有以下公式: 其中R1代表氢原子或较低的烷基,R2代表氢原子、较低的烷基或芳基,环A和/或B未取代或被一个或多个卤素、硝基、三氟甲基、较低烷基或较低烷氧基所取代;包括化合物(I)的6-位氮原子或化合物(II)的4-位氮原子可以形成N-氧化物的情况,以及化合物(I)可以以其药学上可接受的酸加盐形式存在。本发明还涉及一种制备这些化合物的方法。化合物(I)和(II)可用作肌肉松弛剂、抗惊厥药、镇静剂、安定剂等。
查看更多

同类化合物

阿斯普尼辛B 阿斯普尼辛 D 阿斯普尼辛 苯佐莫文 新骏河毒素 乙酰胺,N-(4-硝基-2-吡啶基)-,氧化(9CI) TAK960抑制剂 PLK1抑制剂(RO3280) 8H-嘧啶并[4,5-b][1,4]二氮杂卓 8-甲基-5,9-二氢-6H-嘧啶并[4,5-b][1,4]重氮基庚英-6-酮 6H-嘧啶并[4,5-b][1,4]二氮杂卓 4-甲基-6,11-二氢-3H-嘧啶并[4,5-b][1,5]苯并二氮杂卓-2,5-二酮 2-氯-7,7-二氟-5-甲基-5,7,8,9-四氢-6H-嘧啶基[4,5-B][1,4]二氮杂-6-酮 2-氯-5-甲基-5,7,8,9-四氢-6H-嘧啶[4,5-B][1,4]二氮杂6-酮 1H-嘧啶并[4,5-b][1,4]二氮杂卓 4-amino-8-(1,3-benzodioxol-5-yl)-6-phenyl-8,9-dihydro-7H-pyrimido[4,5-b][1,4]diazepine 2-(2-Bromo-4-isopropyl-phenyl)-4-methyl-6-pentyl-6,7,8,9-tetrahydro-2H-2,3,5,6,9a-pentaaza-benzo[cd]azulen-1-one 2-chloro-8-(trifluoromethyl)-6H,11H-benzo[b]pyrimidino[5,4-f]-1,4-diazaperhydroepin-5-one 4,5,6,7-tetrahydro-2,4-diphenyl-4,7a,12b-triazadibenzo[e,g]azulene-1,3,8-trione 4,5,6,7-tetrahydro-4-methyl-2-phenyl-4,7a,12b-triazadibenzo[e,g]azulene-1,3,8-trione N-(4-((8,9-dimethoxy-5-methyl-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-11H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-5-methyl-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-fluorophenyl)-N-(4-((8-methoxy-2-methyl-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-fluorophenyl)-N-(4-((8-methoxy-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-11H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide di-tert-butyl (1r,4r)-4-(4-(9-cyclohexyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxybenzamido)cyclohexyl phosphate 2-(2-Bromo-4-isopropyl-phenyl)-6-(1-ethyl-propyl)-4-methyl-6,7,8,9-tetrahydro-2H-2,3,5,6,9a-pentaaza-benzo[cd]azulen-1-one 7,8,9,10-tetrahydro-10-hydroxy-9-heptyl-[1,4]diazepino[1,2,3-g,h]purine 7,8,9,10-tetrahydro-10-hydroxy-9-methyl-9-propyl[1,4]diazepino[1,2,3-g,h]purine 6-cyclopentyl-9-[(3-methoxyphenyl)amino]-2-methyl-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-3-one 6-cyclopentyl-9-[(2-methoxyphenyl)amino]-2-methyl-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-3-one tert-butyl 8,10-dibromo-7-oxo-1,2,5,5a,6,7-hexahydro-[1,4]diazepino[1,7-a]quinazoline-3(4H)-carboxylate tert-butyl 8,10-dimethyl-7-oxo-1,2,5,5a,6,7-hexahydro-[1,4]diazepino[1,7-a]quinazoline-3(4H)-carboxylate 11-Diallylaminoacetyl-6-isopropyl-5,6-dihydropyrimido[4,5-b][1,5]benzodiazepin-5-one 6-butyl-11-diallylaminoacetyl-2-phenyl-5,6-dihydropyrimido[4,5-b][1,5]benzodiazepin-5-one 11-chloroacetyl-6-isopropyl-5,6-dihydropyrimido[4,5-b][1,5]benzodiazepin-5-one 4-[(2-cyclopentyl-4,4,6-trimethyl-5-oxo-2,6,9,11-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-10-yl)amino]benzoic acid 4-[(2-cyclopentyl-6-methyl-5-oxo-2,6,9,11-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-10-yl)amino]-3-methoxy-N-(4-piperidyl)benzamide 4-[(6-cyclopentyl-2-methyl-3-oxo-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-9-yl)amino]-N-(1-ethyl-4-piperidyl)-3-methoxy-benzamide 8-(4-chlorophenyl)-6-phenyl-9H-pyrimido[4,5-b][1,4]diazepin-4-ol 1-chloro-7-methoxy-8-(3-morpholin-4-yl-propoxy)-10,11-dihydro-5H-2,4,5,11-tetraaza-dibenzo[a,d]cycloheptene 4-[(6-cyclopentyl-2-methyl-3-oxo-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-9-yl)amino]-3-methoxy-N-methyl-benzamide (S)-tert-butyl (4-chloro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-7-yl)carbamate 3-methoxy-4-[[6-(2-methoxyethyl)-2-methyl-3-oxo-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-9-yl]amino]-N-(1-methyl-4-piperidyl)benzamide (9aS,9R)-4-chloro-N-(4-methylphenyl)-9a,10,11,12-tetrahydro-9H-pyrimido[4,5-b]dipyrrolo[1,2-d:2',1'-g][1,4]diazepin-9-amine